What Purity Products UROX formula reveals about the future of urological wellness
A representative image depicting natural supplement capsules, reinforcing the rise of clinically formulated nutraceuticals like MyBladder® in urological wellness.
Could Vanda’s success with NEREUS revive interest in neurokinin-1 pathways?
NEREUS becomes first FDA-approved motion sickness drug in 40 years. Find out how this approval could reshape antiemetic strategies across industries.
Overture’s titanium implant sees rising use in patients too young for total knee replacement
Overture Orthopaedics hits $1M in sales for its knee resurfacing system targeting early OA. Find out what this milestone reveals about joint preservation.
What Lumos Infinitas’ CES showcase reveals about the next wave of physiological sensing
Find out how Lumos Infinitas’ photonics platform could shift clinical sensing and where adoption hurdles remain. Read analysis and expert insight.
Can Mabwell’s anti-IL-11 antibody redefine scarring treatment through fibrosis reversal?
Mabwell doses first patient in Phase II trial of IL-11 antibody for pathological scarring. Find out what this means for fibrosis drug development.
HAI Solutions earns FDA De Novo clearance for QIKCAP UVC IV disinfection device
HAI Solutions has received De Novo classification from the U.S. Food and Drug Administration (FDA) for its QIKCAP System, making it the first ultraviolet light-based microbial reduction device to be granted such approval for use with needleless luer-activated IV connectors. The FDA decision establishes a new Class II medical device category, placing the QIKCAP platform […]
Co-Diagnostics secures Australian patent for Co-Dx PCR platform, marking global IP expansion milestone
Co-Diagnostics, Inc. has received its first international patent for its Co-Dx PCR platform, with the Australian Patent Office granting coverage for the point-of-care molecular diagnostics system, including its PCR Pro instrument and disposable test cups. This development marks a critical step in the U.S.-based company’s international intellectual property strategy as it advances toward global commercialization […]
Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines
Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.
Will AI-native drug discovery platforms create a new biotech category in 2026?
As 2026 begins, a new class of biotechnology companies is gaining prominence, not for any single drug, but for how they discover them. These firms, often referred to as AI-native biotechs, are reengineering the drug discovery process around machine learning. Unlike traditional pharmaceutical companies that apply algorithms to specific decision points in an existing workflow, […]
Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy
Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical […]